These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 5012204)

  • 1. Regulatory aspects of parenteral drugs.
    Jennings J
    Bull Parenter Drug Assoc; 1972; 26(2):53-7. PubMed ID: 5012204
    [No Abstract]   [Full Text] [Related]  

  • 2. PDA presentation at FDA Open Conference on Sterile Drug Manufacturing. Parenteral Drug Association.
    J Pharm Sci Technol; 1994; 48(1):4-6. PubMed ID: 8004417
    [No Abstract]   [Full Text] [Related]  

  • 3. Assuring the quality of the nation's drugs. Interview by William E. Small.
    Michels D
    Am Pharm; 1980 Apr; NS20(4):40-2. PubMed ID: 7386377
    [No Abstract]   [Full Text] [Related]  

  • 4. The brand name versus generic controversy: Is there a segment of the pharmaceutical industry that produces drugs of higher quality?
    Marsh DA; Hoar ME
    Contemp Pharm Pract; 1982; 5(2):130-5. PubMed ID: 10317245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An FDA update on GMP's for aseptic processing.
    Fry EM
    J Parenter Sci Technol; 1985; 39(4):154-7. PubMed ID: 3928863
    [No Abstract]   [Full Text] [Related]  

  • 6. Improving drug quality through certification experience.
    Weiss PJ
    Am J Pharm Sci Support Public Health; 1974; 146(3):86-90. PubMed ID: 4852375
    [No Abstract]   [Full Text] [Related]  

  • 7. Assuring total drug quality.
    Simmons HE
    J Am Pharm Assoc; 1973 Feb; 13(2):96-8. PubMed ID: 4686621
    [No Abstract]   [Full Text] [Related]  

  • 8. Regulatory issues of parenteral equipment and systems.
    Avallone H
    J Parenter Sci Technol; 1988; 42(3):89-93. PubMed ID: 3216268
    [No Abstract]   [Full Text] [Related]  

  • 9. Use of microbiology in drug monitoring.
    Kirshbaum A
    Bull Parenter Drug Assoc; 1971; 25(5):226-32. PubMed ID: 5109889
    [No Abstract]   [Full Text] [Related]  

  • 10. Determination of particulate matter in large volume parenterals.
    Krueger EO
    Bull Parenter Drug Assoc; 1972; 26(2):96-100. PubMed ID: 5012209
    [No Abstract]   [Full Text] [Related]  

  • 11. Quality assurance for medical products: unified program for all federal agencies.
    Flaherty FJ
    Hosp Formul; 1976 Dec; 11(12):669, 674, 679. PubMed ID: 1028796
    [No Abstract]   [Full Text] [Related]  

  • 12. Securing the US pharmaceutical supply.
    Somberg JC
    Am J Ther; 2008; 15(3):197. PubMed ID: 18496255
    [No Abstract]   [Full Text] [Related]  

  • 13. Response to the applicability of proposed large volume parenteral regulations to small volume parenteral drug products.
    Bull Parenter Drug Assoc; 1976; 30(6):265-79. PubMed ID: 1000103
    [No Abstract]   [Full Text] [Related]  

  • 14. FDA inspections of large volume and small volume parenteral manufacturers.
    Shepherd RE
    Bull Parenter Drug Assoc; 1976; 30(5):209-13. PubMed ID: 974306
    [No Abstract]   [Full Text] [Related]  

  • 15. USP general chapter <797> pharmaceutical compounding-sterile preparations.
    Hung JC
    J Nucl Med; 2004 Jun; 45(6):20N, 28N. PubMed ID: 15181114
    [No Abstract]   [Full Text] [Related]  

  • 16. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. United States Food and Drug Administration's viewpoint.
    Ley HL; Desmond FH
    Can Med Assoc J; 1968 Feb; 98(6):318-21. PubMed ID: 5636100
    [No Abstract]   [Full Text] [Related]  

  • 17. Report on the PQRI impurity characterization and quantification best practices survey.
    Faustino P; Chan CC; Carrano J; Gosnell M; Gu ZQ; Maule A; Sigvardson K; Zhang YF
    Pharm Res; 2006 Feb; 23(2):440-6. PubMed ID: 16477396
    [No Abstract]   [Full Text] [Related]  

  • 18. Drugs and biologics in pregnancy and breastfeeding: FDA in the 21st century.
    Kweder SL
    Birth Defects Res A Clin Mol Teratol; 2008 Sep; 82(9):605-9. PubMed ID: 18704917
    [No Abstract]   [Full Text] [Related]  

  • 19. International Conference on Harmonisation; guidance on Q9 Quality Risk Management; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2006 Jun; 71(106):32105-6. PubMed ID: 16795933
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parenteral Drug Association response to FDA proposal to prohibit the use of any antimicrobial preservative in single-dose parenteral drug products.
    J Parenter Sci Technol; 1985; 39(6):231-2. PubMed ID: 4093824
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.